🔗 Share this article

Given that the United States undertakes historic adjustments to its vaccine recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by questioning COVID-19 vaccines throughout the pandemic and has concentrated on possible fatalities after Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Schedule

Health officials were set to reveal sweeping revisions to the childhood immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would place the US at odds with a large portion of the international standard with insufficient data for improved outcomes. The announcement has been pushed back until the new year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this calendar year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon dismantling long-standing vaccines at the FDA.

Høeg has frequently advocated for halting certain pediatric shot schedules in the US to become more in line with Denmark, a society with universal health coverage and a citizenry about the size of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccines – usually the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Expertise

The appointee has little discernible experience in drug development, approval processes or leadership, which has been typical for past directors of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a major agency. She lacks background in pharmaceutical oversight.”

Previous heads of CBER would “understand laws and regulations and the science of drug development”, noted a former acting FDA commissioner. “Clearly, she lacks the kind of background that previous people who ran CBER have had.”

This division has an vast workload at the FDA, the former commissioner stated.

“The public just pays attention on the innovative therapies, but the off-patent medication office authorizes numerous generic medications. There’s a biologic copycat branch, OTC medication office and so forth, and all of those need to be looked after,” Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major management element to the role, which manages over 5,000 personnel. “It is a enormous leadership role, if you execute it properly,” Woodcock added.

Official Statement and Contentious Initiatives

Regarding questions about Høeg’s qualifications and whether this assignment indicates increased cooperation among agency officials on immunizations, a press secretary stated that the “questions rely on flawed assumptions”.

“Her resume is consistent with the functions of her position,” the spokesperson explained, noting the period Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a contentious one-day therapy clearance system that apparently troubled her preceding directors. “By what process are these therapies being selected for this voucher program? Who takes the decisions?” Howard questioned. “There’s a lot of secrecy happening at the FDA right now.”

In general, he remarked, “the FDA appears to be shifting towards laxer oversight of pharmaceuticals, aside from immunizations.”

Established Past Work on Immunizations

With vaccines, Høeg has a more documented, if troubling, track record, Howard have noted. She authored a research paper using unverified volunteer-provided data to assess the incidence of heart inflammation after COVID-19 immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are riskier than they are.

Part of her “policy goals” for the incoming government featured revising rules for recently developed shots and discontinuing “optional” immunizations, she stated post-election on a online show. At the FDA, Dr. Høeg has according to sources floated the idea of preventing young men from obtaining COVID-19 vaccines.

“She’s an thorough ideologue who starts off with her preconceived notions and works backwards to fit the evidence in a highly deceptive, dishonest fashion,” Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow skeptics, {like|